James Edgar

Part of Evergreen Holdco 2 Ltd., Sygil Group Ltd. is a holding British company that provides drug discovery services. The company is based in Nottingham, UK and was founded in 2011.

Part of Aghoco (1579) Topco Ltd., Aghoco 1578 (Midco) Ltd. operates as a holding British company whose subsidiary manufactures drugs. The company is based in Nottingham, UK and was founded in 2017.

Part of Aghoco (1579) Topco Ltd., RenaSci Ltd. provides pharmacy consulting services. The company is based in Nottingham, UK. The British company was founded in 2001 by Sharon Crawford Cheetham, Robert Brian Jones, David John Heal.

Part of Aghoco (1579) Topco Ltd., Aghoco 1566 (Bidco) Ltd. functions as an investment holding British company. The company is based in Nottingham, UK.

Part of Aghoco (1579) Topco Ltd., Evergreen Holdco 1 Ltd. operates as a holding British company with subsidiaries that engage in research and experimental development on biotechnology. The company is based in Nottingham, UK.

Aghoco (1579) Topco Ltd. is a British biotechnology company founded in 2017. The private company is based in Nottingham, UK. and has subsidiaries in United Kingdom. Aghoco engages in research and development in biotechnology.

Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France.

Aptuit LLC engages in the development of pharmaceutical and biotechnological products. Its offerings include drug design and discovery, preclinical biosciences, API development and manufacture, solid state chemistry, solid and oral dosage form development and manufacture, integrated drug discovery and drug development, Aptuit INDiGO, and physical and analytical chemistry services. The company was founded in December 2004 and is headquartered in Greenwich, CT.

Part of Sygnature Discovery Ltd., SB Drug Discovery Ltd. is a British company that specializes in ion channel services. The company is based in Glasgow, UK. The company offers a portfolio of electrophysiology assays and customized cell line development capabilities to aid in ion channel drug discovery. The company's services include ion channel screening, receptor and enzyme studies, and custom cell line generation expertise. The company also provides a comprehensive panel of sodium (Nav) channel cell lines and assays, as well as HTS and selectivity profiling services to advance hit-to-lead campaigns. The company was founded in 2002. SB Drug Discovery was acquired by Sygnature Discovery Ltd. on January 17, 2023.